Background
Amyotrophic lateral sclerosis (ALS) is a fatal disease in which degeneration of upper and lower motor neurons leads to progressive weakness of bulbar, limb, thoracic, and abdominal muscles with relative sparing of oculomotor muscles and sphincter function. Although the clinical manifestations and pathological changes have been known since the time of Charcot and Joffroy,' the cellular and molecular processes leading to the selective loss of motor neurons are not understood. Recent developments in research on ALS, and in particular, the identification of mutations in the gene encoding Cu/Zn superoxide dismutase (CuZnSOD) in patients with the familial form of ALS2 may provide new treatment strategies. Although familial ALS accounts for only 5%-10% of all patients with ALS,3 4 it iS indistinguishable clinically from sporadic ALS. 6 It is likely, therefore, that understanding of the mechanisms leading to motor neuron degeneration in familial ALS may provide fundamental insights into the pathogenesis of the sporadic form as well.
The family of superoxide dismutase enzymes, of which CuZnSOD is one, comprises a series of important physiological antioxidant defence mechanisms in aerobic organisms.7 Superoxide dismutases inactivate the superoxide radical (02--) generated as a byproduct of normal and aberrant metabolic reactions by converting 02--into hydrogen peroxide (H20,) and oxygen (02):
02-+ 2-+2H+ -H202 +02 (1) Impaired activity of this reaction will lead to the generation of an excess of superoxide radicals. The potentially damaging role of this excess superoxide lies not in its direct action on biological targets, as superoxide is not capable of setting off free radical chain reactions on its own, but in the formation of much more reactive species-for example, hydroxyl radicals (OH), reactions 2 and 3, and peroxynitrite (ONOO-), reaction 4.
02-+ 2-+ 2H+ -H202 + 02 (2) Fe2+ + H202 -. Fe3++-OH + OH-(3) 02-+ -NO ONOO- (4) On the other hand, an excess of these enzymes will increase removal of superoxide with overproduction of H202 and its derivatives, again resulting in oxidative damage. In addition to its primary role in the inactivation of the superoxide, CuZnSOD is also involved in the generation of the free radicals89 and in the nitration of tyrosine residues.'0 Under normal physiological conditions these reactions are kept to a minimum by relatively low concentrations of H202 and NO and by CuZnSOD exercising its essential antioxidant role. However, it seems that ALS associated mutant CuZnSOD enzyme, in an in vitro system at least, becomes a free radical generator to a greater extent than a wild type CuZnSOD."
Mutations in the CuZnSOD gene The gene that encodes CuZnSOD is located on the long arm of chromosome 21 (21q22 1) and is present as a single copy per haploid genome spanning 11 kb of chromosomal DNA.'2 There are five rather small exons that encode 153 amino acids and four introns that interrupt the coding region. Since 1993, 43 different point mutations involving 31 distinct codons,' 3-36 a two base pair substitution at codon 6,'3 a deletion at codon 126,38 and a single base pair substitution in intron 425 have been described (fig 1) . No mutation has been found in exon 3. The highest rate of substitutions relative to the number of base pairs occurs in exon 4, suggesting that certain areas of the CuZnSOD gene are mutational "hot spots". Gly93, seems to be particularly vulnerable; it is substituted with six new amino acids. Two of these, Asp and Arg, alter the charge equilibrium but it is the introduction of the side chains at position 93 that is critical for the stability of the backbone conformation. Fifteen more mutations result in the charge change but only two (Aspl25His, Asnl39Lys) are relevant for the electrostatic attraction of the superoxide and which are likely to affect the function of the enzyme.
The mutations can be classified into four categories: (1) mutations that alter the length of the coding sequence; (2) mutations in the active site channel of the enzyme; (3) mutations at Cu binding sites; and (4) mutations that affect the structure of the protein.
In addition, Leu84 can indirectly destabilise the Cu ligand His46.
MUTATIONS AT CU BINDING SITES
The essential part of the CuZnSOD dismutation reaction lies in the ability of the redoxactive Cu centre to oxidise superoxide in one state and to reduce it in another. This Cu centre is stabilised by four His residues (His46, His48, His63, and His120). His63 also links Cu with Zn and is the one which is involved in the dismutation reaction. His48 and His 120 also seem to play an important part in the loop conformation and interaction between structural elements. Mutations have been found in His46 and His48 but not in His63 and His120. predict the age at onset, distribution, and likely prognosis on the basis of the particular genetic defect. Some attempts, however, have been made to correlate the activity of CuZnSOD in extracts of red blood cells or lymphoblastoid cell lines with age of disease onset and its duration.4'485 These have not produced convincing evidence that severity of disease arises from the loss of enzymatic activity. This is not surprising as the activity of enzymes in critical tissues in other neurological disorders may not be reflected by their activity in erythrocytes.5660
The presenting symptoms in patients with familial ALS are similar to those with sporadic ALS; most of the cases present with the first symptoms in the limbs and only around 20% present with bulbar symptoms.5 These symptoms may develop earlier in life in patients with familial ALS than in the those with sporadic ALS.6' 62 Early onset (below 50 years) is associated with longer survival63 and some younger patients with familial ALS tend to run a slightly longer course.6' Nevertheless, survival of patients with familial ALS tends to be shorter than in patients with sporadic disease.5 Familial ALS occurs in men and women at roughly the same frequency6' 62 whereas in sporadic ALS more men are affected than women. 5 The mean age of onset of disease varies from as early as 28-0 years31 to 61-2 years,4' with the youngest patient developing symptoms at the age of 6.' When the same mutation (for example, Gly37Arg, His46Arg, Ilel 12Thr, Ile 1 3Thr) is present in more than one family the mean age of onset in each of these families seems to be similar. However, there might also be a difference of up to 15 years in the mean onset of the disease in families with the same mutation.5'
CuZnSOD gene mutations are associated with a rapidly progressive form ( fig 3A) , a classic form (fig 3B) , and a relatively benign form of ALS ( fig 3C) A relatively mild form of ALS is associated with a number of CuZnSOD mutations ( fig  3C) with all but a few patients living longer than eight years after the onset of the disease. 25 28 31 41 47 53 56 Most of these patients presented with ALS at around 45 or even earlier.
However, the patients in these families with onset in their 60s or later had a relatively good prognosis as well. Patients with (apparently) sporadic ALS with homozygous Asp90Ala mutation have the same benign form of ALS as those with familial ALS who are homozygous for the Asp9OAla mutation.56 However, some of the patients with sporadic ALS who are heterozygous for the Asp90Ala mutation present with classic,"5 (and Enayat et al, unpublished data) or even rapidly progressive ALS. 23 There is thus no clear correlation between the site of mutations in the CuZnSOD gene and their predicted effects on enzyme function, or the age of onset or duration of ALS. However, it is striking that all CuZnSOD gene mutations for which clinical data are available are associated with onset in the limb rather than in the bulbar musculature. It is conceivable that the apparent lack of correlation between the site of mutations and clinical features of the disease reflects the incompletness of data. In 56 of the known 121 families there is no information available on the number of affected people, age of onset, duration of disease, and site of onset. Twelve of these mutations are particularly interesting as they appear in more than one family and clinical data relating to some of these families are presented in this review. It will be important to know if all families with the Ala4Val mutation behave similarly to the 14 families reported by Bowling and associates4' or if Scottish and American Ile 1 3Thr families show the variability of the English Ilel l3Thr family.52 Of course, it will be of the utmost importance to learn if all these patients with familial ALS presented with limb onset.
There is no clear relation between mutations in highly conserved regions of the gene (indicating functionally important residues) and the age of onset or severity. Mutations in these critical residues might be expected to cause rapidly progressive ALS, and although some are associated with a rapid course-for example, Gly37Arg, His48Gln, Leu84Val, and Serl 34Asn-others are linked to mild forms of ALS-for example, Gly37Arg, His46Arg, and Gly93Asp. In addition, mutations in less highly conserved sites (hence less important for normal functioning of the enzyme) are associated with rapidly progressive ALS-for example, the Cys6Phe mutation.
The evidence outlined suggests that the phenotype of subjects with CuZnSOD mutations is determined by factors other than the site of the mutation. These factors could be environmental, or genetic, or both. A search for genetic modifying factors may be the most productive approach, given the failure of epidemiological studies to identify significant environmental risk factors.65 It could be argued that there is selection bias with respect to families with CuZnSOD gene mutation as they were sought specifically for linkage analysis, and probably reflect highly penetrant mutations. Caution is therefore needed in making genotype/phenotype correlations and population based studies are necessary to understand the complex interactions between gene-gene and gene-environment. 45 Pathology There have been few reports to date on the molecular pathology of ALS associated with CuZnSOD gene mutations. 54 66-68 Many of the patients have shown neurofilamentous accumulations in lower motor neurons, and in one patient there were also neurofilamentous accumulations in Betz cells of the primary motor cortex.67 Ubiquitinated inclusions in anterior horn cells have also been noted in some of these patients and in one family, these inclusions were also labelled by antibody against CuZnSOD.6' Proximal axonal swellings containing bundles of neurofilaments have long been recognised as a feature of both sporadic and familial ALS, and alterations in the phosphorylation state of neurofilaments in anterior horn cells have been described. 70 The nature of the relation between CuZnSOD mutations and neurofilamentous inclusions is unclear, but it is possible that the mutations lead to altered neurofilament function, or to changes in axonal transport. It is interesting that mutations of neurofilament genes have been identified in a few patients with (apparently) sporadic ALS,7' and in transgenic mice certain neurofilament gene mutations also lead to progressive loss of motor neurons.72 At present there is no evidence that neurofilamentous inclusions and axonal spheroids represent a primary pathogenic change in familial or sporadic ALS, but neurofilament dysfunction possibly triggered by CuZnSOD mutations may none the less contribute to neuronal damage. Finally, it is worth nothing that intraneuronal vacuoles, which are prominent in transgenic models, are absent in familial ALS with CuZnSOD mutations.
In summary, the molecular pathology of familial ALS with CuZnSOD mutations differs in some striking respects from the findings in transgenic mice (table 2) . 40 73 74 fibroblasts,2' and brain40 75 (fig 4) . In some patients, however, the mutant dimer may have a dominant negative effect on the activity and longevity of the wildtype subunit48 although this is an exception rather than a rule, and the activity of CuZnSOD in red blood cells of patients with ALS homozygous for the Asp9OAla mutation is essentially normal.23
The specific activity of the enzyme is also fully retained in transfected COS-1 cells with the humnan CuZnSOD gene carrying the Gly37Arg mutation.73 When the same mutation is introduced into transgenic mice the animals develop features of lower motor neuron disease with CuZnSOD in the spinal cord increased sevenfold to 14-fold, whereas mice expressing the wild type human CuZnSOD 
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